Difference between revisions of "Idecabtagene vicleucel (Abecma)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/idecabtagene-vicleucel NCI Drug Dictionary]: A preparation of autologous peripheral blood T lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. | |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 8: | Line 8: | ||
*3/26/2021: Approved for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. ''(Approval based on KarMMa)'' | *3/26/2021: Approved for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. ''(Approval based on KarMMa)'' | ||
| − | == Patient Drug Information== | + | ==Patient Drug Information== |
*[https://www.fda.gov/media/147055/download idecabtagene vicleucel (Abecma) Package Insert]<ref>[https://www.fda.gov/media/147055/download idecabtagene vicleucel (Abecma) Package Insert]</ref> | *[https://www.fda.gov/media/147055/download idecabtagene vicleucel (Abecma) Package Insert]<ref>[https://www.fda.gov/media/147055/download idecabtagene vicleucel (Abecma) Package Insert]</ref> | ||
| Line 19: | Line 19: | ||
[[Category:Chimeric antigen receptor T-cells]] | [[Category:Chimeric antigen receptor T-cells]] | ||
| + | [[Category:Anti-BCMA cellular therapy]] | ||
| + | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] | ||
Revision as of 21:24, 29 April 2022
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous peripheral blood T lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (Approval based on KarMMa)
Patient Drug Information
Also known as
- Code name: bb2121
- Generic name: ide-cel
- Brand name: Abecma